Food Allergy Market to Witness Growth by 2032, Estimates DelveInsight | Companies- Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company, Vedanta Biosciences, Regeneron Pharmaceu

DelveInsight's "Food Allergy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Food Allergy, historical and forecasted epidemiology as well as the Food Allergy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Food Allergy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Food Allergy market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Food Allergy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Food Allergy market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Food Allergy: An Overview

According to National Institute of Allergy and Infectious Diseases (NIAID), a food allergy is an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food. Food allergens are the parts of food or ingredients within food (usually proteins) that are recognized by immune cells. When an immune cell binds to a food allergen, a reaction occurs that causes the symptoms of food allergy. "Allergy" and "allergic disease" refer to conditions that involve changes to the immune system. These immune system changes fall into two categories: Immunoglobulin E (IgE) mediated and Non-IgE-mediated.
The symptoms of food allergies range from mild discomfort to severe, life-threatening reactions, which require immediate medical intervention. Symptoms may be triggered in the skin (itching, redness, swelling), gastrointestinal tract (pain, vomiting, diarrhea, itching and swelling of oral cavity), respiratory tract (itching and swelling of the nose and throat, asthma), eyes (itching and swelling), and/or cardiovascular system (e.g. chest pain, abnormal heart rhythm).
The cause of food allergy can be functional genetic variants in the IL-12 receptor b1, Toll-like receptor 9, and thymic stromal lymphopoietin genes and even IL-4 gene polymorphism have been associated with an increased risk of food sensitization.
Diagnosis of a food allergy relies on patient history and physical exam. The most common diagnosis method for food allergy according to World Allergy Organization (WAO) include Skin prick tests (SPT), which is the preferred testing method in those patients with a history compatible with food allergies; double blind placebo-controlled food challenge (DBPCFC), which is the preferred test to diagnose food allergy; the in vitro diagnostics can help to identify cross-reactive allergens between pollen and foods, or foods and latex, and the atopy patch test (APT) is an epicutaneous skin test in which allergens commonly associated with IgE reactions can be used.
The treatment of food allergy relies on avoidance of the foods to which an individual is allergic, as therapeutic intervention (tertiary prevention) in patients with food allergy. Unfortunately, severe reactions such as anaphylaxis may occur despite best efforts in avoidance. Epinephrine is the first-line medication for the treatment of anaphylaxis. Additional medications include H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors these drugs are only symptomatic, do not modify the natural course of the disease.
Treatment of food allergy is a rapidly changing landscape, with arguably, the most significant advancement in recent years, the transition of oral immunotherapy (OIT) to clinical practice. As an innovation, OIT is a phase of rapidly increasing demand, particularly for some allergens such as peanut, egg, and milk, which have substantial evidence of efficacy.
The Food Allergy market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies by major key players in the treatment regime. The launch of various multiple-stage pipeline products will significantly revolutionize the Food Allergy market dynamics shortly.

Learn more about Food Allergy, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Food Allergy Market

This section includes a glimpse of the Food Allergy market in 7MM, Canada and China. The market size of Food Allergy was found to be USD 2,028.97 million in 2021.

The Food Allergy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Food Allergy market trends by analyzing the impact of current Food Allergy therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

According to DelveInsight, the Food Allergy market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Food Allergy Epidemiology

The total 7MM, Canada and China prevalent cases of Food Allergy were 285,039,654 in 2021.

The Food Allergy epidemiology section provides insights into the historical and current Food Allergy patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Food Allergy market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Food Allergy Epidemiology at: https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Food Allergy Emerging Drugs
Ligelizumab: Novartis Pharmaceuticals
From December 10, 2021, Novartis Pharmaceuticals, will initiate a 52-week, multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) injection every 4 weeks (SCq4w) in participants with a medically confirmed diagnosis of IgE-mediated peanut allergy. The participants will be randomized to ligelizumab 240 mg, Ligelizumab 120 mg, or placebo (5 treatment arms, randomization ratio of 2:2:2:2:1) for the double-blind placebo-controlled treatment period (up to Week 12).
The primary outcome measure includes the proportion of participants who can tolerate a single dose of ≥ 600 mg (1044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms at Week 12. The study will enroll 486 participants and get completed by May, 2025.

Food Allergy Pipeline Development Activities

The Food Allergy report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Food Allergy key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Food Allergy pipeline development activities at: https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Food Allergy Therapeutics Assessment

Major players Ligelizumab (Novartis Pharmaceuticals), Viaskin Peanut (DBV Technologies), INP20 (InnoUp Farma S.L.), Omalizumab (Genentech, Inc. /Novartis Pharmaceuticals/Rho Federal Systems Division, Inc.) etc being assessed as potential therapies to be available in the market in the coming future.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Food Allergy Report Key Insights

1. Food Allergy Patient Population
2. Food Allergy Market Size and Trends
3. Key Cross Competition in the Food Allergy Market
4. Food Allergy Market Dynamics (Key Drivers and Barriers)
5. Food Allergy Market Opportunities
6. Food Allergy Therapeutic Approaches
7. Food Allergy Pipeline Analysis
8. Food Allergy Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Food Allergy Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Food Allergy Competitive Intelligence Analysis
4. Food Allergy Market Overview at a Glance
5. Food Allergy Disease Background and Overview
6. Food Allergy Patient Journey
7. Food Allergy Epidemiology and Patient Population
8. Food Allergy Treatment Algorithm, Current Treatment, and Medical Practices
9. Food Allergy Unmet Needs
10. Key Endpoints of Food Allergy Treatment
11. Food Allergy Marketed Products
12. Food Allergy Emerging Therapies
13. Food Allergy Seven Major Market Analysis
14. Attribute Analysis
15. Food Allergy Market Outlook (7 major markets)
16. Food Allergy Access and Reimbursement Overview
17. KOL Views on the Food Allergy Market
18. Food Allergy Market Drivers
19. Food Allergy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Food Allergy Market report here: https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.